• FDA updates breast implant–associated lymphoma cases, risk

    on March 22nd, 2018
    The Food and Drug Administration has received 414 reports of cases of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL), including nine deaths. This figure includes all medical device reports received by the agency between 2011 and September 2017. The FDA recently provided an upd[...]
  • Low microbiota diversity linked to poor survival after transplant

    on March 22nd, 2018
    REPORTING FROM THE 2018 BMT TANDEM MEETINGS SALT LAKE CITY (FRONTLINE MEDICAL NEWS) – A multicenter study confirmed that diversity of gut microbiota is associated with better survival after allogeneic hematopoietic cell transplantation (HCT), while low diversity and the predominance of pathogenic [...]
  • Protons linked to lower urinary AEs, higher costs than with IMRT for prostate cancer

    on March 22nd, 2018
    FROM JOURNAL OF CLINICAL ONCOLOGY Among men younger than 65 with prostate cancer, proton beam radiotherapy (PBT) was associated with significantly lower rates of urinary toxicities than was intensity-modulated radiotherapy (IMRT), but this safety advantage came at the cost of nearly $60,000 extra pe[...]
  • Accelerated breast irradiation advocated by ASTRO guideline

    on March 21st, 2018
    FROM PRACTICAL RADIATION ONCOLOGY Hypofractionation is the preferred means of giving whole breast irradiation to women with invasive breast cancer, according to updated guidance from the American Society for Radiation Oncology. A dose of 4,000 cGy given in 15 fractions or 4,250 cGy in 16 fractions i[...]
  • H. pylori eradication cuts new gastric cancers by half

    on March 21st, 2018
    FROM THE NEW ENGLAND JOURNAL OF MEDICINE Treatment for Helicobacter pylori infection cut the incidence of new gastric cancers in half among patients undergoing endoscopic resection of early gastric cancer, according to results of a recent randomized, placebo-controlled study. Patients receiving H. p[...]
  • TACE plus radiotherapy improves outcomes in poor-prognosis hepatocellular carcinoma

    on March 21st, 2018
    FROM JAMA ONCOLOGY Use of transarterial chemoembolization (TACE) plus external beam radiotherapy may improve outcomes in patients with hepatocellular carcinoma (HCC) showing macroscopic vascular invasion, according to results of a recent randomized study. The TACE plus radiotherapy approach was well[...]
  • FDA approves new option in Hodgkin lymphoma treatment

    on March 20th, 2018
    The Food and Drug Administration has approved brentuximab vedotin, in combination with chemotherapy, for previously untreated adults with stage III or IV classical Hodgkin lymphoma. The drug, which is marketed by Seattle Genetics as Adcetris, is already approved in classical Hodgkin lymphoma after r[...]
  • Fulvestrant plus neratinib reversed treatment-acquired HER2 mutations in metastatic ER+ breast cancer

    on March 19th, 2018
    FROM THE AACR 2018 ANNUAL MEETING Dual therapy with fulvestrant and the irreversible HER2 kinase inhibitor neratinib reversed treatment-acquired hormone resistance in metastatic estrogen receptor (ER)–positive breast cancer cells. Elaine Mardis, PhD, a spokesperson for the American Association of [...]
  • Chlamydia infections associated with more than a doubling of ovarian cancer risk

    on March 16th, 2018
    FROM THE AACR ANNUAL MEETING Pelvic inflammatory disease caused by chlamydia appears to significantly increase the risk of ovarian cancer, according to research to be presented at the annual meeting of the American Association for Cancer Research. The finding, replicated in two large databases, sugg[...]
  • cSCC staging systems poorly determine metastasis risk

    on March 15th, 2018
    FROM JAMA DERMATOLOGY Current staging systems for cutaneous squamous cell carcinoma (cSCC) poorly discerned between patients with and without metastases, according to researchers. In a population-based case-control study of 6,721 cSCC patients, the American Joint Committee on Cancer, 7th edition (AJ[...]
  • Time to rethink MCL treatment, trial design

    on March 14th, 2018
    FROM JAMA ONCOLOGY Classic mantle cell lymphoma (cMCL) has long been treated as a uniformly aggressive disease in need of similarly aggressive treatment, but that approach may be leading to overtreatment, according to one expert. “The cMCL encompasses a broad category of lymphomas with highly vari[...]
  • CAR T before transplant yields durable remission in B-cell malignancies

    on March 14th, 2018
    REPORTING FROM THE 2018 BMT TANDEM MEETINGS SALT LAKE CITY (FRONTLINE MEDICAL NEWS) – Chimeric antigen receptor (CAR) T-cell therapy may be an effective bridge to hematopoietic cell transplant (HCT) for high-risk B-cell malignancies, according to a systematic analysis of patient data from the Nati[...]
  • Emerging data help inform immunotherapy for urothelial cancer

    on March 14th, 2018
    REPORTING FROM GUCS 2018 SAN FRANCISCO (FRONTLINE MEDICAL NEWS) – Emerging data from phase 3 clinical trials are better clarifying the efficacy and safety of immunotherapy in advanced urothelial cancer and helping identify patients most likely to benefit. An updated analysis of the KEYNOTE-045 tri[...]
Back to top